Bortezomib for acute antibody-mediated rejection in liver transplantation

F. Paterno, M. Shiller, G. Tillery, J. G. O'Leary, B. Susskind, J. Trotter, G. B. Klintmalm

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Antibody-mediated rejection (AMR) is an uncommon, but challenging type of rejection after solid organ transplantation. We review three cases of AMR in ABO-compatible liver transplant recipients. These cases were characterized by severe acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma cell infiltrates, C4d positivity and high serum anti-HLA donor-specific antibodies. All three patients were treated with bortezomib, a proteasome inhibitor effective in depleting plasma cells. After treatment, all patients had improved or normal liver function tests, resolution of C4d deposition and significant decline in their HLA donor-specific antibodies. This study reviews three cases of acute antibody-mediated rejection in ABO-compatible liver transplant recipients treated with proteasome-inhibitor therapy (bortezomib) with remarkable clinical, immunologic and histologic outcomes.

Original languageEnglish (US)
Pages (from-to)2526-2531
Number of pages6
JournalAmerican Journal of Transplantation
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

Liver Transplantation
Antibodies
Proteasome Inhibitors
Plasma Cells
Tissue Donors
Antilymphocyte Serum
Liver
Liver Function Tests
Organ Transplantation
Steroids
Bortezomib
Therapeutics
Serum
Transplant Recipients

Keywords

  • Antibody-mediated rejection
  • bortezomib
  • crossmatch
  • donor-specific antibodies
  • HLA compatibility
  • liver transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Paterno, F., Shiller, M., Tillery, G., O'Leary, J. G., Susskind, B., Trotter, J., & Klintmalm, G. B. (2012). Bortezomib for acute antibody-mediated rejection in liver transplantation. American Journal of Transplantation, 12(9), 2526-2531. https://doi.org/10.1111/j.1600-6143.2012.04126.x

Bortezomib for acute antibody-mediated rejection in liver transplantation. / Paterno, F.; Shiller, M.; Tillery, G.; O'Leary, J. G.; Susskind, B.; Trotter, J.; Klintmalm, G. B.

In: American Journal of Transplantation, Vol. 12, No. 9, 01.09.2012, p. 2526-2531.

Research output: Contribution to journalArticle

Paterno, F, Shiller, M, Tillery, G, O'Leary, JG, Susskind, B, Trotter, J & Klintmalm, GB 2012, 'Bortezomib for acute antibody-mediated rejection in liver transplantation', American Journal of Transplantation, vol. 12, no. 9, pp. 2526-2531. https://doi.org/10.1111/j.1600-6143.2012.04126.x
Paterno, F. ; Shiller, M. ; Tillery, G. ; O'Leary, J. G. ; Susskind, B. ; Trotter, J. ; Klintmalm, G. B. / Bortezomib for acute antibody-mediated rejection in liver transplantation. In: American Journal of Transplantation. 2012 ; Vol. 12, No. 9. pp. 2526-2531.
@article{63a50c608fc0419798d65dd34e100305,
title = "Bortezomib for acute antibody-mediated rejection in liver transplantation",
abstract = "Antibody-mediated rejection (AMR) is an uncommon, but challenging type of rejection after solid organ transplantation. We review three cases of AMR in ABO-compatible liver transplant recipients. These cases were characterized by severe acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma cell infiltrates, C4d positivity and high serum anti-HLA donor-specific antibodies. All three patients were treated with bortezomib, a proteasome inhibitor effective in depleting plasma cells. After treatment, all patients had improved or normal liver function tests, resolution of C4d deposition and significant decline in their HLA donor-specific antibodies. This study reviews three cases of acute antibody-mediated rejection in ABO-compatible liver transplant recipients treated with proteasome-inhibitor therapy (bortezomib) with remarkable clinical, immunologic and histologic outcomes.",
keywords = "Antibody-mediated rejection, bortezomib, crossmatch, donor-specific antibodies, HLA compatibility, liver transplantation",
author = "F. Paterno and M. Shiller and G. Tillery and O'Leary, {J. G.} and B. Susskind and J. Trotter and Klintmalm, {G. B.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1111/j.1600-6143.2012.04126.x",
language = "English (US)",
volume = "12",
pages = "2526--2531",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Bortezomib for acute antibody-mediated rejection in liver transplantation

AU - Paterno, F.

AU - Shiller, M.

AU - Tillery, G.

AU - O'Leary, J. G.

AU - Susskind, B.

AU - Trotter, J.

AU - Klintmalm, G. B.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Antibody-mediated rejection (AMR) is an uncommon, but challenging type of rejection after solid organ transplantation. We review three cases of AMR in ABO-compatible liver transplant recipients. These cases were characterized by severe acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma cell infiltrates, C4d positivity and high serum anti-HLA donor-specific antibodies. All three patients were treated with bortezomib, a proteasome inhibitor effective in depleting plasma cells. After treatment, all patients had improved or normal liver function tests, resolution of C4d deposition and significant decline in their HLA donor-specific antibodies. This study reviews three cases of acute antibody-mediated rejection in ABO-compatible liver transplant recipients treated with proteasome-inhibitor therapy (bortezomib) with remarkable clinical, immunologic and histologic outcomes.

AB - Antibody-mediated rejection (AMR) is an uncommon, but challenging type of rejection after solid organ transplantation. We review three cases of AMR in ABO-compatible liver transplant recipients. These cases were characterized by severe acute rejection resistant to steroids and antithymocyte globulin, histologic evidence of plasma cell infiltrates, C4d positivity and high serum anti-HLA donor-specific antibodies. All three patients were treated with bortezomib, a proteasome inhibitor effective in depleting plasma cells. After treatment, all patients had improved or normal liver function tests, resolution of C4d deposition and significant decline in their HLA donor-specific antibodies. This study reviews three cases of acute antibody-mediated rejection in ABO-compatible liver transplant recipients treated with proteasome-inhibitor therapy (bortezomib) with remarkable clinical, immunologic and histologic outcomes.

KW - Antibody-mediated rejection

KW - bortezomib

KW - crossmatch

KW - donor-specific antibodies

KW - HLA compatibility

KW - liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=84865593513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865593513&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2012.04126.x

DO - 10.1111/j.1600-6143.2012.04126.x

M3 - Article

C2 - 22681986

AN - SCOPUS:84865593513

VL - 12

SP - 2526

EP - 2531

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 9

ER -